Research & Development: Page 48
-
PharmaVoice Team/PharmaVoice
Seeing the Big Picture With Visual Data Analytics
Pharmaceutical and biotechnology companies are facing a gigantic increase in data — not just in volume, but in complexity. The number of clinical trials in the National Institute of Health’s registry has jumped from 5,635 in 2000 to 183,991 in 2015 — an increase of more than 30 times. The data la...
By Greg Moody • June 1, 2015 -
PharmaVoice Team/PharmaVoice
All Monitoring is Risk Based
Drug developers must introduce innovation across the entire life cycle of product development to more effectively bring new therapies to markets. The innovations will be recognized by the use of smarter and faster methods for discovery of new drug entities and companion diagnostics, use of flexib...
By Michael Brooks • June 1, 2015 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Managing the Scientific and Ethical Complexities of Medical Innovation
Today, advances in science and medicine are occurring at an unprecedented pace. These exciting changes broaden the ethical implications of medical innovation and expand the need to protect clinical research subjects. Often, Institutional Review Boards (IRBs) find themselves on the frontline of th...
By Lindsay McNair • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Maximizing Portfolio Value By Smart Partnering: This is Not Your Father's Oldsmobile
Portfolio value is traditionally associated with innovation value; i.e., intellectual property, market attractiveness, potential clinical utility, and other product-centric attributes. Less commonly considered is the differentiation afforded by the partnering process employed during clinical deve...
By Michael Murphy • June 1, 2015 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
In this month’s Forum, experts from multiple disciplines, from drug development to marketing, discuss the challenges and opportunities that technology is bringing to the table. AstraZeneca’s CIO David Smoley sums up the changing landscape neatly: “When it comes to IT, we cannot operate in a world...
By Taren Grom • May 1, 2015 -
PharmaVoice Team/PharmaVoice
UpFront
Industry at Large AbbVie To Award 40 CF Scholarships AbbVie has announced the 2015 AbbVie CF Scholarship, which honors and supports young adults with cystic fibrosis (CF) as they pursue higher education, is now open to undergraduate and graduate students. For the 23rd year, the AbbVie CF Scholar...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Automating Medicinal Chemistry Through Building Blocks Martin Burke, M.D., Ph.D., and Mark Goldsmith, M.D., Ph.D., founded Revolution Medicines, which has an automated chemical synthesis platform that can be used to produce a broad range of molecules. Through the years of trial and error, researc...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
What's New
Turing Pharmaceuticals New Drug Company Launched Trending now: Experienced team comes together to focus on treating unmet medical needs. Turing Pharmaceuticals, a new pharmaceutical company, launched with news of three acquisitions for its commercial operations and development pipeline. New York-...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Pharma Trax
Cancer Care in America: A Shifting Landscape Trending now: Amid growing patient demand and administrative burden, there are stresses on the oncology care system. The U.S. cancer care system faces tremendous turbulence while dealing with growing numbers of cancer patients and survivors, mounting ...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
On the Calendar
Coming Attractions DIA 2015, the 51st annual meeting, is the largest multidisciplinary event that brings together a global network of life-sciences professionals to foster innovation that will lead to the development of safe and effective medical products and therapies to patients. This year’s t...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biopharma Pool Steven Ertel Dr. Matthew Sherman Acceleron Pharma Announces Executive Appointments and Promotions Acceleron Pharma, a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic candidates that regulate cellular growth...
By PharmaVoice Team • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Last Word
Enabling Cancer Immunotherapies Henry Li, Ph.D., VP, Translational Oncology at Crown Bioscience, talks about the challenges of developing new and novel cancer immunotherapeutics. PV: Cancer immunotherapy is a hot area of research now. Why do you think this is? Li: Cancer chemotherapies are toxic ...
By Henry Li • May 1, 2015 -
PharmaVoice Team/PharmaVoice
3D Applications in Medicine
Three-dimensional printing is no longer simple plastic prototypes. Today, 3-D printers can produce fully functional components, including complex mechanisms, batteries, transistors, and LEDs. 3D printing — also known as additive manufacturing — is the process of making three-dimensional solid obj...
By Denise Myshko • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Early Cancer Detection
For most cancers, diagnosis happens too late, when the cancer has worsened or metastasized. But when cancers are diagnosed early, survival statistics are much higher. For example, the five-year survival rate for patients diagnosed with colorectal cancer is around 90% if diagnosed when the cancer ...
By Denise Myshko • May 1, 2015 -
PharmaVoice Team/PharmaVoice
2015 HBA Luminaries
The Importance of Mentoring and Sponsorship Emily Lightfoot. AmerisourceBergen. Relationships with mentors have been the key to my career success. Having an advocate and coach to help me plan my career, discover my strengths, and identify opportunities has helped me develop confidence to take on ...
By Taren Grom • May 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology Pool Mary Thistle Dimension Names Chief Business Officer Dimension Therapeutics, a rare disease company advancing novel treatments for diverse genetic disorders of the liver based upon an AAV gene therapy platform, has appointed Mary Thistle to the newly created position of chief bu...
By PharmaVoice Team • April 1, 2015 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
A New Way to KILL INFECTIONS Mark Offerhaus, Chief Executive of the Dutch firm Micreos, talks about the company’s antibiotic alternative that uses endolysins. Antibiotic resistance is increasingly becoming a serious global threat to public health and is the cause of many common infections, includ...
By Mark Offerhaus • March 1, 2015 -
PharmaVoice Team/PharmaVoice
Pharma Trax
Putting the “e" in Patient-Reported Outcomes Trending now: Electronic data collection improves data quality, shortens study timelines, and increases the likelihood of regulatory approval. Although transitioning from a pen-and-paper strategy to an electronic patient-reported outcome (ePRO) approac...
By PharmaVoice Team • March 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology Pool Tony Hunt Repligen Names CEO Repligen, a life-sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs, has appointed Tony Hunt as CEO. Mr. Hunt, currently Repligen’s chief operatin...
By PharmaVoice Team • March 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Executive appointments and promotions in the healthcare industry Pharma Pool Dr. Julie Gerberding Merck Strengthens Executive Team Merck has named Julie Gerberding, M.D., as executive VP for strategic communications, global public policy and population health. In this newly created executive comm...
By PharmaVoice Team • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Last Word
Addressing the Needs of THOSE WITH RARE DISEASES Peter Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), talks about recent orphan drug approvals. PV: 2014 was a record year for orphan drug approvals. What are your predictions for the orphan drug space for 201...
By Peter Saltonstall • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
A New Frontier: Bioelectronics Medicines
The nervous system is essentially the body’s electrical and communication system that wires together all the nerves and organs — starting at the brain and central cord and branching out to every other part of the body. Technological advances have led researchers to consider how the nervous system...
By Denise Myshko • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Outsourcing: Outsourcing in a New Era
Companies continue to examine new ways to optimize operations and capitalize on efficiencies through partnerships. As the industry continues to move to a more patient-centric model, which encompasses all aspects of the continuum from R&D through commercialization, CROs and other service partn...
By Taren Grom • Feb. 1, 2015 -
PharmaVoice Team/PharmaVoice
Talent Pool
Executive appointments and promotions in the healthcare industry Pharma Pool Stephen Aselage Retrophin Appoints CEO Retrophin has appointed Stephen Aselage as CEO; he has served as the company’s interim CEO since Sept. 30, 2014. Mr. Aselage has more than 30 years of pharmaceutical and biotechnolo...
By PharmaVoice Team • Jan. 1, 2015 -
PharmaVoice Team/PharmaVoice
C-Suite: Clinical Services
We asked C-suite executives throughout the clinical services ecosystem to provide their insights on what the biggest opportunities for innovation are, what the biggest barriers are, and identify a recent innovation that is improving the process. Dr. Martine Dehlinger-Kremer Global VP, Medical an...
By Taren Grom • Jan. 1, 2015
Previous
